In contrast, RAF265 seems to achieve plasma levels that are commensurate with active exposures in preclinical models; however, the agent may not have sufficient selectivity for BRAFV600E in most patients, as indicated by the increased incidence of thrombocytopenia and visual side effects—both more consistent with inhibition of wild‐type BRAF and CRAF, and decreased incidence of skin squamous cell carcinoma. The gene discussed is BRAF; the disease is skin squamous cell carcinoma.